[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
From the JAMA Network
July 28, 2015

Empirical Therapy of Community-Acquired Pneumonia: Advancing Evidence or Just More Doubt?

Author Affiliations
  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  • 2Department of Medicine, University of Western Australia, Perth, Australia
  • 3Department of Medicine, Northwestern University, Chicago, Illinois
JAMA. 2015;314(4):396-397. doi:10.1001/jama.2015.3858

Pneumonia remains a significant cause of morbidity and mortality, whether community acquired (CAP) or hospital acquired. Although many microbial pathogens may cause pneumonia, the most commonly encountered are pneumococcus; atypical organisms, such as Mycoplasma pneumoniae or Legionella; and at times Staphylococcus aureus and certain gram-negative rods. As diagnostic tests have increased in availability and sophistication, identifying multiple pathogens in the same patient is increasingly common.